Tag: Braftovi
Pierre Fabre receives EC nod for colorectal cancer drug
Laboratoires Pierre Fabre has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with cetuximab and FOLFOX for the first-line treatment...
Nanoform outlicenses nanoencatafenib and signs development and commercialisation agreement
Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, announced that it has established, in collaboration with A.forall Development NV, a wholly owned subsidiary of...
Pierre Fabre gets China nod for cancer drug
Pierre Fabre Laboratories, the world’s second-largest dermo-cosmetics company, has announced that the Chinese authorities granted the marketing authorization for Braftovi, in combination with cetuximab,...
Pierre Fabre Laboratories receives CHMP positive opinion for Braftovi in combination...
Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of Braftovi (encorafenib)...